National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 2) (PB 14 of 2021) (Cth)
PB 14 of 2021
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 2)
National Health Act 1953
___________________________________________________________________________
I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the
National Health Act 1953.
Dated 24 February 2021
THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 2).
(2)This Instrument may also be cited as PB 14 of 2021.
Commencement
This Instrument commences on 1 March 2021.
Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).
Schedule 1 Amendments
Schedule 1, after entry for Duloxetine
insert:
| Dupilumab | Injection 200 mg in 1.14 mL single dose pre-filled syringe | 20 | 2 | 5 |
| Injection 300 mg in 2 mL single dose pre-filled syringe | 20 | 2 | 5 |
Schedule 1, entry for Esomeprazole
substitute:
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | 20 | 30 | 1 |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Capsule (enteric) 40 mg (as magnesium) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Tablet (enteric coated) 20 mg (as magnesium trihydrate) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Tablet (enteric coated) 40 mg (as magnesium trihydrate) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 |
Schedule 1, entry for Lansoprazole
substitute:
| Lansoprazole | Capsule 15 mg | 20 | 30 | 5 |
| Capsule 30 mg | 20 | 28 | 1 | |
| 20 | 28 | 5 | ||
| 20 | 56 | 5 | ||
| Tablet 15 mg (orally disintegrating) | 20 | 28 | 5 | |
| Tablet 30 mg (orally disintegrating) | 20 | 28 | 1 | |
| 20 | 28 | 5 | ||
| 20 | 56 | 5 |
Schedule 1, entry for Mesalazine
substitute:
| Mesalazine | Sachet containing granules, 500 mg per sachet | 20 | 200 | 5 |
| Sachet containing granules, 1 g per sachet | 20 | 100 | 5 | |
| Sachet containing granules, 1.5 g per sachet | 20 | 60 | 5 | |
| Sachet containing granules, 3 g per sachet | 20 | 30 | 5 | |
| Sachet containing prolonged release granules, 1 g per sachet | 20 | 100 | 5 | |
| 20 | 120 | 5 | ||
| Sachet containing prolonged release granules, 2 g per sachet | 20 | 60 | 5 | |
| Sachet containing prolonged release granules, 4 g per sachet | 20 | 30 | 5 | |
| Tablet 250 mg (enteric coated) | 20 | 100 | 5 | |
| Tablet 500 mg (enteric coated) | 20 | 200 | 5 | |
| Tablet 500 mg (prolonged release) | 20 | 200 | 5 | |
| Tablet 800 mg (enteric coated) | 20 | 180 | 5 | |
| Tablet 1 g (enteric coated) | 20 | 120 | 5 | |
| Tablet 1 g (prolonged release) | 20 | 120 | 5 | |
| Tablet 1.2 g (prolonged release) | 20 | 120 | 5 |
Schedule 1, after entry for Nifedipine in the form Tablet 20 mg
insert:
| Tablet 20 mg (controlled release) | 20 | 30 | 5 |
Schedule 1, entry for Omeprazole
substitute:
| Omeprazole | Capsule 20 mg | 20 | 30 | 1 |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Tablet 10 mg (as magnesium) | 20 | 30 | 5 | |
| Tablet 20 mg | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Tablet 20 mg (as magnesium) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 |
Schedule 1, after entry for Oxybutynin in the form Transdermal patches 36 mg, 8
insert:
| Ozanimod | Capsule 920 micrograms | 20 | 28 | 5 |
| Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms | 20 | 1 | 0 |
Schedule 1, entry for Pantoprazole
substitute:
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | 20 | 30 | 1 |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 | ||
| Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | 20 | 30 | 5 | |
| Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 |
Schedule 1, entry for Phenoxybenzamine
insert as first entry:
| Capsule containing 10 mg phenoxybenzamine hydrochloride | 20 | 100 | 5 |
Schedule 1, entry for Rabeprazole
substitute:
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | 20 | 28 | 5 |
| Tablet containing rabeprazole sodium 20 mg (enteric coated) | 20 | 30 | 1 | |
| 20 | 30 | 5 | ||
| 20 | 60 | 5 |
0
0
0